Price targets

Analyst ratings

8 analysts rated this company in the past 90 days. The average target price is €60.07, this is a change of +17.2% compared to the current price.

• September 22, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained a "neutral" rating on Novo Nordisk with a price target of DKK 340. In a study released Monday, Matthew Weston examined the latest weekly US prescription trends for Novo Nordisk's weight-loss drug Wegovy and competing products. As expected, Wegovy prescriptions for new patients declined after jumping following a decision by the pharmacy chain CVS to favor Wegovy over Eli Lilly's Zepbound as its preferred drug./rob/gl/men

  Publication of the original study: September 22, 2025 / 10:54 a.m. / GMT. First distribution of the original study: September 22, 2025 / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 18, 2025

  Deutsche Bank maintains Novo Nordisk's 'Buy' rating - target 600 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Novo Nordisk with a price target of 600 Danish kroner. Emmanuel Papadakis wrote in a study released Friday that the recent price rally is not based on new information, but rather on depressed sentiment and valuation. However, the pharmaceutical company needs an improvement in prescription trends in the coming weeks to ensure a more sustainable development./edh/stw

  Publication of the original study: September 18, 2025 / Time not specified in the study / CET

  First distribution of the original study: September 18, 2025 / 8:05 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 18, 2025

  Deutsche Bank maintains Novo Nordisk's 'Buy' rating - target 600 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Novo Nordisk with a price target of 600 Danish kroner. The European Diabetes Association (EASD) has been rather uneventful so far, wrote Emmanuel Papadakis in a study published Thursday. More remarkable, however, is the flood of warning letters that the US Food and Drug Administration (FDA) recently sent to manufacturers of cheap copies of the weight-loss drugs. This is a step in the right direction./edh/tav

  Publication of the original study: September 18, 2025 / Time not specified in the study / CET

  First distribution of the original study: September 18, 2025 / 8:02 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 18, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 500 kroner

  NEW YORK (dpa-AFX Analyser) - The US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 500 Danish kroner. In a study published Thursday, Richard Vosser addressed statements on research and development (R&D) at the EASD 2025 Diabetes Conference. Regarding the R&D strategy, the pharmaceutical company's management emphasized that the focus remains on obesity and diabetes, as well as the comorbidities associated with these diseases./rob/edh/stk

  Publication of the original study: September 18, 2025 / 6:36 a.m. / BST

  First distribution of the original study: September 18, 2025 / 6:36 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 17, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS maintained its rating for Novo Nordisk at "Neutral" with a price target of DKK 340 following an investor event on the sidelines of the EASD 2025 Diabetes Conference. The pharmaceutical company had previously presented its strategy for a broader positioning in light of the future segmentation of the obesity market, Matthew Weston wrote in a study released Thursday. Therefore, the conference did not provide any significant new information. However, the analyst believes Novo's broader focus makes sense./rob/edh/tav

  Publication of the original study: September 17, 2025 / 8:47 PM / GMT

  First distribution of the original study: September 18, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 16, 2025

  Berenberg upgrades Novo Nordisk to 'Buy' - lowers target to 425 kroner

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has upgraded Novo Nordisk from "Hold" to "Buy," but lowered its price target from 610 to 425 Danish kroner. Since its share price peak in mid-2024, the pharmaceutical company has lowered its targets several times, and market expectations have been significantly lowered, wrote Kerry Holford in a reassessment published Wednesday. This allows for a more constructive view of growth prospects, price drivers, and valuation. Despite remaining obstacles, the new CEO now has the opportunity to deliver a positive surprise. The stock is replacing that of US competitor Eli Lilly as its preferred stock in the treatment of obesity./rob/gl/edh

  Publication of the original study: September 16, 2025 / 5:10 p.m. / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 15, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 340 Danish kroner. Matthew Weston addressed current prescription trends for weight-loss medications (GLP-1) in his weekly report published on Tuesday./rob/edh/tih

  Publication of the original study: September 15, 2025 / 10:45 a.m. / GMT

  First distribution of the original study: September 15, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation for conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 15, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of DKK 340. Matthew Weston reported on current weekly prescription trends for weight-loss medication (GLP-1) in a study released Monday. Following a change at retailer CVS, which sees Novo's Wegovy as its preferred drug over Eli Lilly's Zepbound, growth is slowing again./niw/la

  Publication of the original study: September 15, 2025 / 10:45 / GMT

  First distribution of the original study: September 15, 2025 / 10:45 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 11, 2025

  Deutsche Bank Research maintains Novo Nordisk's 'Buy' rating

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "Buy" rating on Novo Nordisk with a price target of 600 Danish kroner. Emmanuel Papadakis wrote in an assessment released Thursday that he has adjusted his valuation model for the pharmaceutical company to reflect the announced restructuring and the resulting costs, as well as the recent below-average share price performance. The stock's outlook for the third fiscal quarter appeared good.

  Publication of the original study: September 11, 2025 / 9:25 a.m. / CET. First distribution of the original study: Date not specified in study / Time not specified in study / CET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 10, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained a "neutral" rating on Novo Nordisk with a price target of 340 Danish kroner. The pharmaceutical company's announced restructuring program is the first action of the new CEO, wrote Matthew Weston in a study published Wednesday. After a period of strong personnel growth, the reduction in headcount shifts the focus to reducing corporate complexity. The crucial question now is when the resulting freed-up funds, which should be reinvested in growth, will be reflected in sales./rob/gl/jha/

  Publication of the original study: September 10, 2025 / 7:04 a.m. / GMT First distribution of the original study: September 10, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 10, 2025

  JPMorgan leaves Novo Nordisk at 'Overweight' - target 500 kroner

  NEW YORK (dpa-AFX Analyst) - Following the announcement of a restructuring program, US bank JPMorgan has maintained Novo Nordisk's "Overweight" rating with a price target of DKK 500. Richard Vosser, in his reaction released Wednesday, noted that the pharmaceutical company is taking action to reduce the complexity of its business model and increase its agility. However, the move is likely to raise questions about growth prospects./rob/gl/jha/

  Publication of the original study: September 10, 2025 / 7:51 a.m. / BST First distribution of the original study: September 10, 2025 / 7:51 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 8, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 340 Danish kroner. Matthew Weston reported on current weekly prescription trends for weight-loss medication (GLP-1) in a study released Monday. Following a change at retailer CVS, which now sees Novo's Wegovy as its preferred drug ahead of Eli Lilly's Zepbound, the expert believes Wegovy's growth is currently peaking. This fits with its expectation of slower growth./tih/gl

  Publication of the original study: September 8, 2025 / 10:35 a.m. / GMT First distribution of the original study: September 8, 2025 / 10:35 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 8, 2025

  Bernstein upgrades Novo Nordisk to 'Outperform' - target 540 kroner

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has upgraded its rating for Novo Nordisk from "Market-Perform" to "Outperform," but lowered its price target from DKK 620 to DKK 540. Analyst Florent Cespedes explained his new rating on Tuesday evening, arguing that the growth potential of the obesity medication business is underestimated. This also reflects the sharp drop in share price. On Wednesday, he wrote that the announced job cuts were a surprise, but more in terms of the timing than the measures themselves. He expects the pharmaceutical company to record a special charge in 2025 in this context./mis/tih

  Publication of the original study: September 8, 2025 / 3:40 p.m. / UTC

  First distribution of the original study: September 9, 2025 / 3:35 p.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 5, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of DKK 340. Weekly prescription figures for GLP-1 weight-loss drugs indicate a stable market, Matthew Weston wrote on Friday. However, Wegovy's market share has declined slightly./rob/ag/bek

  Publication of the original study: September 5, 2025 / 10:49 a.m. / GMT

  First distribution of the original study: September 5, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 3, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 500 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained Novo Nordisk's "Overweight" rating with a price target of 500 Danish kroner. Richard Vosser adjusted his valuation model for the pharmaceutical company on Wednesday evening based on the latest quarterly figures. The expert stated that the estimates have not changed, as they already take into account the new outlook from the end of July./rob/gl/ag

  Publication of the original study: September 3, 2025 / 5:58 PM / BST First distribution of the original study: September 4, 2025 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 1, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of DKK 340. New prescriptions for the weight-loss drug Wegovy rose slightly in the week ending August 22, while they declined slightly for Zepbound, a competitor in the GLP-1 class, Matthew Weston wrote on Monday. Zepbound's market share also declined slightly./rob/ag/la

  Publication of the original study: September 1, 2025 / 11:27 a.m. / GMT

  First distribution of the original study: September 1, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 29, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss major bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 340 Danish kroner. The market remained stable overall, Matthew Weston wrote on Friday after analyzing weekly prescription figures for GLP-1 weight-loss drugs./ag/he

  Publication of the original study: August 29, 2025 / 11:09 / GMT First distribution of the original study: August 29, 2025 / 11:09 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 26, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner. In a study published Tuesday, Florent Cespedes referred to study results from US competitor Eli Lilly in the field of weight-loss medications. The American company's drug, orforglipron, is a serious competitor for Novo Nordisk, as weight-loss pills remain an attractive option. It confirms that there is no one-win scenario in the area of obesity.

  Publication of the original study: August 26, 2025 / 3:46 PM / UTC

  First distribution of the original study: August 26, 2025 / 3:46 PM / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 21, 2025

  Deutsche Bank maintains Novo Nordisk's 'Buy' rating - target 600 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Novo Nordisk with a price target of 600 Danish kroner. In a study published Thursday, Emmanuel Papadakis assessed the pharmaceutical company's recent news cycle, supplemented by the influence of other companies' products. In summary, the developments are slightly positive for Novo Nordisk – especially in the area of oral obesity therapy, as this significantly reduces the risk of replacing conventional injection therapies./tih/edh

  Publication of the original study: August 21, 2025 / Time not specified in study / CET

  First distribution of the original study: August 21, 2025 / 8:05 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 18, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of DKK 340. Matthew Weston analyzed the weekly new prescription figures for the GLP-1 weight-loss drug on Monday afternoon. For Wegovy from the Danes, they fell less sharply than for Zepbound from competitor Eli Lilly./ag/gl

  Publication of the original study: August 18, 2025 / 1:34 PM / GMT First distribution of the original study: August 18, 2025 / 1:34 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 18, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of DKK 340 following another US approval for the weight-loss drug Wegovy. The approval came earlier than expected and is therefore positive, wrote Matthew Weston in an initial reaction released on Monday. The US Food and Drug Administration (FDA) had previously approved Wegovy for the treatment of moderate to advanced non-alcoholic fatty liver disease./rob/edh/tih

  Publication of the original study: August 18, 2025 / 6:56 a.m. / GMT

  First dissemination of the original study: August 18, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 11, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyser) - The Swiss major bank UBS has left its rating for Novo Nordisk at "neutral" with a price target of 340 Danish kroner. The increase in prescriptions for the active ingredient semaglutide in the US has recently lagged behind that of its competitor Eli Lilly, wrote Matthew Weston in a study published Tuesday./rob/bek/la

  Publication of the original study: August 11, 2025 / 1:10 p.m. / GMT First distribution of the original study: August 11, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 8, 2025

  Bernstein leaves Novo Nordisk at 'Market-Perform' - 620 kroner

  NEW YORK (dpa-AFX Analyser) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner. In a study released Monday, Florent Cespedes refers to an investor event with the pharmaceutical company's new head of product and portfolio management. Whether the situation in the US will improve quickly with regard to essentially illegal generic competitors for weight-loss medications remains unclear. However, this is already reflected in the new company outlook./rob/mis/tih

  Publication of the original study: August 8, 2025 / 4:02 PM / UTC

  First distribution of the original study: August 8, 2025 / 4:02 PM / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 8, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of DKK 340 in light of weekly prescription statistics for GLP-1 weight-loss pills. As Matthew Weston wrote in a study published Friday, the market is currently developing stably overall. Looking ahead, he expects slower sequential growth given the continued presence of compounders./rob/tih/jha/

  Publication of the original study: August 8, 2025 / 10:56 AM / GMT

  First distribution of the original study: August 8, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 7, 2025

  Goldman lowers target for Novo Nordisk to 392 kroner - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has lowered its price target for Novo Nordisk from 400 to 392 Danish kroner, but maintained its "buy" rating. Investors are currently very concerned, and the negative sentiment could persist until the end of the year, James Quigley wrote in a study released Friday. However, the company underestimates the sales potential in the area of anti-obesity medications. The expert considers the poor share price performance following the latest quarterly report to be exaggerated./tih/mis

  Publication of the original study: August 7, 2025 / 5:06 a.m. / BST

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 7, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyser) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner. In an assessment released Thursday, Florent Cespedes referred to a study on the weight-loss pill Orforglipron from US competitor Eli Lilly that was received with disappointment in the market. The study results on Orforglipron are not directly comparable with the data on Novo Nordisk's weight-loss pills, which contain the active ingredient semaglutide. He maintains that the weight-loss pills remain an attractive option for the Danes. The expert expects the US Food and Drug Administration (FDA) to approve the drug towards the end of the year./rob/la/he

  Publication of the original study: August 7, 2025 / 12:26 / UTC. First distribution of the original study: August 7, 2025 / 12:26 / UTC.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 7, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 500 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of DKK 500. A study by competitor Eli Lilly on the drug orforglipron shows disappointing levels of weight loss, wrote Richard Vosser in a study released Thursday. This reduces the competitive risk for the Danish pharmaceutical company./rob/tih/he

  Publication of the original study: August 7, 2025 / 1:06 PM / BST First distribution of the original study: August 7, 2025 / 1:15 PM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 7, 2025

  Deutsche Bank lowers Novo Nordisk target to 600 kroner - 'Buy'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research lowered its price target for Novo Nordisk from 750 to 600 Danish kroner following detailed quarterly figures, but maintained its "Buy" rating. The final results differed only slightly from the preliminary key figures, but nevertheless caused further significant price losses, wrote Emmanuel Papadakis in a study released Thursday. This offers investors a favorable buying opportunity./edh/bek

  Publication of the original study: August 7, 2025 / Time not specified in the study / CET

  First distribution of the original study: August 7, 2025 / 8:05 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 6, 2025

  Jefferies maintains Novo Nordisk's 'underperform' rating

  NEW YORK (dpa-AFX Analyst) - Following final second-quarter figures, analyst Jefferies maintained its rating for Novo Nordisk at "underperform" with a price target of 415 kroner. The previously published results largely met expectations, wrote Benjamin Jackson in a study released Wednesday. This supports the assumption that the forecast reduction was solely due to growth in the second half of the year. Research and development spending appears to be cut more than usual. However, it remains unclear whether this was a strategic decision or mere coincidence./rob/tih/bek

  Publication of the original study: August 6, 2025 / 2:51 a.m. / Time zone not specified in the study

  First distribution of the original study: August 6, 2025 / 2:51 a.m. / Time zone not specified in the study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 6, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 500 kroner

  NEW YORK (dpa-AFX Analyst) - Following detailed figures, US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of DKK 500. The fact that the weight-loss injection Wegovy exceeded expectations is slightly positive, wrote Richard Vosser in a quick assessment released Wednesday. However, the focus remains on the long-term prospects for GLP-1 diabetes and weight-loss medications./rob/ck/tih

  Publication of the original study: August 6, 2025 / 8:54 a.m. / BST

  First distribution of the original study: August 6, 2025 / 8:54 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 6, 2025

  UBS leaves Novo Nordisk at 'Neutral' - target 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" after final figures, with a price target of DKK 340. The additional details now provided have shown a slightly better-than-expected development for the weight-loss injection Wegovy, as prices in the US have held up quite well compared to the previous quarter, Matthew Weston wrote in a quick assessment released Wednesday. However, the weight-loss drug Ozempic faced this challenge due to the reduction in stocks in China./rob/ck/tih

  Publication of the original study: August 6, 2025 / 6:35 a.m. / GMT

  First distribution of the original study: August 6, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 4, 2025

  UBS lowers Novo Nordisk to 'Neutral' and target to 340 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has downgraded Novo Nordisk from "Buy" to "Neutral" and lowered its price target from 600 to 340 Danish kroner. The Danish pharmaceutical company's "stock story" faces major challenges, wrote Matthew Weston in a study published Tuesday. The outlook for the weight-loss drug Wegovy is uncertain, as are those for the company's cash position. The drug Ozempic appears to have already reached its peak./rob/bek/ck

  Publication of the original study: August 4, 2025 / 9:17 PM / GMT

  First distribution of the original study: August 5, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 4, 2025

  Goldman lowers Novo Nordisk target to 400 kroner - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has lowered its price target for Novo Nordisk from 745 to 400 Danish kroner and maintained its "Buy" rating. Analyst James Quigley, in a report released Monday, cited a profit warning from the insulin and weight-loss product manufacturer as the reason for the price reduction. He admits that his "buy" recommendation hasn't paid off recently, but maintains it despite remaining uncertainties. The sell-off was detached from the company's long-term opportunities with slimming products./tih/mis

  Publication of the original study: August 4, 2025 / 4:09 a.m. / BST

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 1, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyser) - US analyst Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner. While the price reductions for many drugs demanded by US President Donald Trump would be an additional burden for pharmaceutical companies in addition to the US tariffs, they would also be manageable, Florent Cespedes wrote in a study released Friday. The requested actions appear to be limited to Medicaid. This is a government-funded healthcare program for low-income people, the elderly, and people with disabilities./mis/nas

  Publication of the original study: August 1, 2025 / 7:10 a.m. / UTC

  First distribution of the original study: August 1, 2025 / 7:10 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 30, 2025

  Barclays lowers Novo Nordisk to 'Equal Weight' - target 375 kroner

  LONDON (dpa-AFX Analyst) - British investment bank Barclays has downgraded Novo Nordisk from "Overweight" to "Equal Weight" following another profit warning and almost halved its price target from 700 to 375 Danish kroner. Without clear guidance on how semaglutide could return to sales growth, and with the diabetes specialist's pipeline lagging behind that of Eli Lilly, it sees no reason for investors to buy the stock, wrote Emily Field. In its study published on Wednesday, the company stated that it remained convinced that the obesity market would become the largest therapeutic market in history, but at the same time, many of the problems addressed the day before in lowering its forecast appeared to be company-specific./rob/ck/mis

  Publication of the original study: July 30, 2025 / 02:51 / GMT

  First distribution of the original study: July 30, 2025 / 03:05 / GMT

  Note: Information on the disclosure obligation for conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 30, 2025

  JPMorgan lowers Novo Nordisk target to 500 kroner - 'Overweight'

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan lowered its price target for Novo Nordisk from 650 to 500 Danish kroner following the recent profit warning, but maintained its rating at "Overweight." Due to the reduced annual targets, it has reduced its sales growth forecasts for 2025 and 2026, Richard Vosser wrote in a study released Wednesday. Nevertheless, he still sees potential for double-digit growth for the pharmaceutical company this year./rob/edh/ajx

  Publication of the original study: July 30, 2025 / 1:27 a.m. / BST

  First distribution of the original study: July 30, 2025 / 1:27 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 29, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyser) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner, following another lowering of the pharmaceutical company's earnings expectations. Market expectations are now likely to fall, Florent Cespedes wrote in a study released Wednesday. However, the expert also emphasized that the Danish company is getting a new CEO. All in all, there are still opportunities in the weight-loss product business, but competitive pressure remains, and the news situation is likely to remain mixed this year./rob/mis/ajx

  Publication of the original study: July 29, 2025 / 7:02 p.m. / UTC

  First distribution of the original study: July 29, 2025 / 7:02 p.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 29, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 650 kroner

  NEW YORK (dpa-AFX Analyser) - The US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 650 Danish kroner after a profit warning for 2025. The pharmaceutical company's new targets allowed the consensus estimate for operating profit in 2025 to decline by nine percent, wrote Richard Vosser in a study released Tuesday.

  Publication of the original study: July 29, 2025 / 1:24 a.m. / BST First distribution of the original study: July 29, 2025 / 1:24 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 28, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner. Florent Cespedes wrote in an industry study released Monday that the US would apparently impose tariffs of 15 percent on brand-name drugs, while generics would likely not be affected. Overall, the risks for the companies appear manageable, with the impact on the companies' profits potentially reaching a low- to mid-single-digit percentage. Novo Nordisk would be least affected, and UCB likely most affected./mis/ck

  Publication of the original study: July 28, 2025 / 6:49 a.m. / UTC

  First distribution of the original study: July 28, 2025 / 6:49 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 18, 2025

  UBS maintains Novo Nordisk's 'Buy' rating - target 600 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 600 Danish kroner. Novo's Wegovy's share of prescriptions for GLP-1 weight-loss drugs declined slightly last week, Matthew Weston wrote on Friday. New prescriptions have increased – equally for Novo and its US competitor Eli Lilly./rob/ag/jha/

  Publication of the original study: July 18, 2025 / 11:06 a.m. / GMT

  First distribution of the original study: July 18, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 15, 2025

  UBS lowers target for Novo Nordisk to 600 kroner - 'Buy'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has lowered its price target for Novo Nordisk from 700 to 600 Danish kroner, but maintained its "Buy" rating. Analyst Matthew Weston cut his earnings estimates through 2029 by an average of 7 percent ahead of the Danes' quarterly report. He expects them to lower their annual forecast. This could be a cleansing storm, as the focus is on accelerating momentum in the second half of the year. Weston primarily bases the reduction in his estimates on recent currency movements, but also on lower expectations for sales of the diabetes and weight-loss drug Ozempic in the US./rob/ag/zb

  Publication of the original study: July 15, 2025 / 9:12 PM / GMT

  First distribution of the original study: July 16, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 14, 2025

  Berenberg maintains Novo Nordisk on 'Hold' - target 610 kroner

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Hold" rating for Novo Nordisk with a price target of 610 Danish kroner. Following the uneventful ADA (American Diabetes Association) conference in June, analyst Kerry Holford remains cautious on diabetes specialist Novo. Interest is currently focused on the weekly prescription trends for the weight-loss drug Wegovy in the US, she wrote in her commentary published Tuesday. It continues to rely on Eli Lilly and Zealand Pharma in the obesity sector./rob/ck/ag

  Publication of the original study: July 14, 2025 / 4:28 p.m. / Time zone not specified in study

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 11, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 700 Danish kroner. Matthew Weston analyzed the weekly new prescription figures for GLP-1 weight loss drugs on Friday. Overall, a decline was observed, which was significantly smaller for Wegovy from the Danish company than for the competing drug Zepbound from Eli Lilly./rob/ag/gl

  Publication of the original study: July 11, 2025 / 10:58 a.m. / GMT. First distribution of the original study: July 11, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 9, 2025

  Deutsche Bank maintains 'Buy' rating on Novo Nordisk - target 750 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Novo Nordisk with a price target of DKK 750. Analyst Emmanuel Papadakis evaluated surveys conducted by several market researchers in the diabetes sector on Tuesday following the ADA annual meeting. Overall, their results are slightly positive for Novo Nordisk, especially because the move away from so-called "compound products" appears to be gaining momentum./tih/ag

  Publication of the original study: July 9, 2025 / Time not specified in the study / CET

  First distribution of the original study: July 9, 2025 / 8:08 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 2, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 700 Danish kroner. Analyst Matthew Weston commented on Wednesday on the announcement that the benefit management subsidiary CVS Caremark of the US pharmaceutical distributor CVS Health will use Novo's weight-loss drug Wegovy as its preferred medication starting July 1. This is one of many reasons why he expects tailwind for the pharmaceutical company in the second half of the year./rob/tih/ag

  Publication of the original study: July 2, 2025 / 3:18 p.m. / GMT

  First distribution of the original study: July 2, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 30, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 650 kroner

  NEW YORK (dpa-AFX Analyst) - JPMorgan has maintained Novo Nordisk's "Overweight" rating with a price target of 650 Danish kroner. The stock is also on the US bank's "Analyst Focus List." The pharmaceutical company's quarterly figures, due on August 6, are expected to largely meet consensus estimates, and the annual targets will be confirmed, wrote Richard Vosser in his outlook published on Monday./rob/gl/bek

  Publication of the original study: June 30, 2025 / 12:07 AM / BST

  First distribution of the original study: June 30, 2025 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 27, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 700 Danish kroner. Jo Walton again reviewed the weekly first-prescription data for GLP-1 weight-loss drugs on Friday. Novos Zegovy gained slightly, while Eli Lilly's Zepbound recorded a decline./rob/ag/bek

  Publication of the original study: June 27, 2025 / 10:50 a.m. / GMT

  First distribution of the original study: June 27, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 24, 2025

  Deutsche Bank Research maintains Novo Nordisk's 'Buy' rating

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research maintained its "Buy" rating for Novo Nordisk following a visit to a diabetes conference in Chicago, with a price target of 750 Danish kroner. Emmanuel Papadakis drew a mixed conclusion in his review published on Tuesday. He noted that the study data on Cagrisema were solid overall, and that participant interest was very high. However, data on amycretin were not as good./la/ag

  Publication of the original study: June 24, 2025 / Time not specified in the study / CET. First distribution of the original study: June 24, 2025 / 8:13 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 23, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 700 Danish kroner. Jo Walton sees some momentum for prescription numbers in the second half of the year, according to a commentary released Tuesday following an analyst meeting./rob/ag/gl

  Publication of the original study: June 23, 2025 / 6:36 p.m. / GMT First distribution of the original study: June 23, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 23, 2025

  Jefferies leaves Novo Nordisk at 'underperform' - target 415 kroner

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its rating for Novo Nordisk at "underperform" with a price target of 415 Danish kroner. The data from CagriSema's successor to Ozempic came with no surprises, Benjamin Jackson wrote on Monday. Overall, he is skeptical about the company's prospects. The market for weight loss products is becoming increasingly fragmented./ag/gl

  Publication of the original study: June 23, 2025 / 12:29 AM / ET First distribution of the original study: June 23, 2025 / 12:29 AM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 23, 2025

  Barclays maintains Novo Nordisk at 'Overweight' - target 700 kroner

  LONDON (dpa-AFX Analyst) - British investment bank Barclays has maintained its rating for Novo Nordisk at "Overweight" with a price target of 700 Danish kroner following study data on the obesity drug Cagrisema. These results have been well received by clinicians, wrote Emily Field in a study published Monday. Investors, however, remain skeptical.

  Publication of the original study: June 23, 2025 / 03:13 / GMT First distribution of the original study: June 23, 2025 / 03:17 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 23, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 650 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 650 Danish kroner following study data on Cagrisema. The market may have dismissed the obesity drug too quickly, wrote Richard Vosser in a study released Monday. Cagrisema's profile may be more competitive than previously assumed.

  Publication of the original study: June 23, 2025 / 5:56 a.m. / BST First distribution of the original study: June 23, 2025 / 5:56 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 20, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 700 Danish kroner. Weekly prescription trends in the US signaled slight declines for the drugs Wegovy and Zepbound, Jo Walton wrote in a study released Friday. In the previous week, prescriptions for both drugs had increased by double digits./rob/bek/he

  Publication of the original study: June 20, 2025 / 12:11 PM / GMT. First distribution of the original study: June 20, 2025 / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 16, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyser) - The Swiss major bank UBS has maintained Novo Nordisk's "Buy" rating with a price target of 700 Danish kroner. US prescription data for GLP1 weight-loss supplements in the week ending June 6 showed a slightly stronger increase for the Danish company compared to its US competitor Eli Lilly, Jo Walton wrote in a commentary on Monday./gl/edh

  Publication of the original study: June 16, 2025 / 11:02 / GMT First distribution of the original study: June 16, 2025 / 11:02 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 15, 2025

  JPMorgan lowers Novo Nordisk target to 650 kroner - 'Overweight'

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan lowered its price target for Novo Nordisk from 1,000 to 650 Danish kroner, but maintained its "Overweight" rating. The lower price target reflects the pharmaceutical sector's lower valuation and its 16 percent cut in its 2026 earnings (EPS) forecast, Richard Vosser wrote in a study released Monday. However, given the Danes' outstanding growth profile up to 2030 and the even better prospects after 2030, a significantly higher valuation potential compared to the EU pharmaceutical industry is justified./rob/edh/gl

  Publication of the original study: June 15, 2025 / 6:46 PM / BST First distribution of the original study: June 16, 2025 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 13, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of DKK 700. As expected, the number of first-time prescriptions for GLP-1 weight-loss drugs increased in the week ending June 6 compared to the previous week, which included Memorial Day, Jo Walton wrote on Friday. However, Eli Lilly recorded the larger increase./rob/ag/gl

  Publication of the original study: June 13, 2025 / 10:55 a.m. / GMT First distribution of the original study: June 13, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 12, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyser) - US analyst Bernstein Research has maintained Novo Nordisk's "Market-Perform" rating with a price target of 620 Danish kroner. Florent Cespedes wrote in an assessment released Thursday that he does not expect the pharmaceutical company's product portfolio details, which it will present at an American Diabetes Association event, to have a significant impact on the share price. Therefore, it is still too early to take a more positive view of the stock./gl/edh

  Publication of the original study: June 12, 2025 / 5:51 a.m. / UTC First distribution of the original study: June 12, 2025 / 5:51 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 9, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 700 Danish kroner. The number of new US prescriptions for GLP-1 weight-loss drugs fell by double digits during Memorial Day week, Jo Walton wrote on Monday. For the Danes, the decline compared to the previous week across all doses was significantly lower at 11.9 percent compared to competitor Eli Lilly, with its decline of 17.5 percent./rob/ag/bek

  Publication of the original study: June 9, 2025 / 11:07 a.m. / GMT

  First distribution of the original study: June 9, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 6, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of DKK 700 due to recent prescription trends for weight-loss drugs. Weekly market data from the US suggest a decline, Jo Walton wrote in a study released Friday. However, this is likely also due to the "Memorial Day" holiday, which was observed in the US on Monday of that week./rob/tih/he

  Publication of the original study: June 6, 2025 / 10:51 a.m. / GMT First distribution of the original study: June 6, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 2, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk, with a price target of DKK 700, in light of recent data on prescription trends for weight-loss pills. Novo Nordisk's drug Wegovy has recorded the highest increase in new patients since the beginning of the year, Jo Walton wrote in a study released Monday. This could therefore be the beginning of an improvement, even if competitor Eli Lilly's growth remains stronger.

  Publication of the original study: June 2, 2025 / 11:48 AM / GMT

  First distribution of the original study: June 2, 2025 / 11:48 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 27, 2025

  Deutsche Bank maintains 'Buy' rating on Novo Nordisk - target 750 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Novo Nordisk with a price target of DKK 750. Emmanuel Papadakis examined a survey of physicians regarding their prescribing preferences for the weight-loss products Wegovy (Novo Nordisk) and Zepbound (Eli Lilly). The summary shows a slight negative for Novo Nordisk, he wrote in a study published on Tuesday./edh/gl

  Publication of the original study: May 27, 2025 / Time not specified in the study / CET. First distribution of the original study: May 27, 2025 / 7:51 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 19, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 700 Danish kroner. Initial prescriptions for the Danish company's GLP-1 weight-loss products increased by 5 percent in the week ending May 9, while competitor Eli Lilly fell by almost 11 percent, Jo Walton wrote on Monday, referring to recent data. New prescriptions for Novo's Wegovy even rose by 5.6 percent, while those for Lilly's Zepbound fell by a good 21 percent./rob/ag/ajx

  Publication of the original study: May 19, 2025 / 10:54 AM / GMT

  First distribution of the original study: May 19, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 19, 2025

  Deutsche Bank maintains 'Buy' rating on Novo Nordisk - target 750 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Novo Nordisk at "Buy" with a price target of 750 Danish kroner following the announcement of a change in CEO. Emmanuel Papadakis wrote on Monday that the announcement appears somewhat arbitrary both in terms of timing and content. The natural timing for this personnel change would have been before the pharmaceutical company's release of its first-quarter financial results. Now, there is a lack of clarity regarding the criteria for candidates for the top position or the timeline for the new appointment, resulting in a certain degree of uncertainty./la/ajx

  Publication of the original study: May 19, 2025 / Time not specified in the study / CET. First distribution of the original study: May 19, 2025 / 8:00 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 16, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1,000 kroner

  NEW YORK (dpa-AFX Analyst) - JPMorgan has maintained Novo Nordisk's "Overweight" rating with a price target of 1,000 Danish kroner. The stock is also on the US bank's "Analyst Focus List." The announced resignation of CEO Lars Fruergaard Jorgensen was unexpected, wrote Richard Vosser in a response released Friday. However, this step and the replacement of Lars Rebein Sorensen – Jorgensen's predecessor and current chairman of the Novo Nordisk Foundation – were apparently preceded by a mutual agreement. Accordingly, a change in management is in the interest of the pharmaceutical company and its shareholders given the recent market challenges. Novo Nordisk reaffirmed its confidence in the current business plans and emphasized that its strategy remains unchanged./gl/edh

  Publication of the original study: May 16, 2025 / 12:54 PM / BST First distribution of the original study: May 16, 2025 / 1:02 PM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 15, 2025

  Berenberg maintains Novo Nordisk on 'Hold' - target 610 kroner

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained a "Hold" rating on Novo Nordisk with a price target of 610 Danish kroner. Under the Inflation Reduction Act (IRA) of US President Donald Trump's predecessor, drug prices for Americans will fall by an average of almost two-thirds starting in January 2026, wrote Kerry Holford in an industry commentary published Friday. This will save the US government around $6 billion, which pharmaceutical companies and insurers would then have to shoulder. The further price reductions demanded by Trump could push these savings up to $10 billion. The mechanism by which Trump intends to achieve this is unclear. However, verbal pressure on the industry could be enough to obtain concessions./gl/edh

  Publication of the original study: May 15, 2025 / 4:13 PM / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 12, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight'

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,000 Danish kroner. Wegovy and Eli Lilly's competing drug Zepbound are much closer in terms of tolerability than previously thought, Richard Vosser wrote on Monday, referring to new data from the Surmount-5 study. According to an earlier publication, Wegovy was even superior in terms of efficacy. Novo Nordisk shares are on JPMorgan's "Analyst Focus List."/rob/ag/edh

  Publication of the original study: May 12, 2025 / 8:22 a.m. / BST

  First distribution of the original study: May 12, 2025 / 8:23 a.m. / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 12, 2025

  Goldman lowers target for Novo Nordisk to 775 kroner - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has lowered its price target for Novo Nordisk from 825 to 775 Danish kroner, but maintained its "Buy" rating. Due to currency fluctuations, James Quigley lowered his estimates for the pharmaceutical company on Monday following the company's latest quarterly report./ag/la

  Publication of the original study: May 12, 2025 / 5:00 a.m. / BST

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 8, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 700 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 700 Danish kroner. The Danish company's investment story must be proven by results, Jo Walton wrote on Thursday evening after an investor meeting following the quarterly report. The focus remains on US prescription trends./rob/ag/tih

  Publication of the original study: May 8, 2025 / 5:34 PM / GMT

  First distribution of the original study: May 8, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 7, 2025

  UBS lowers target for Novo Nordisk to 700 kroner - 'Buy'

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has lowered its price target for Novo Nordisk from 750 to 700 Danish kroner and maintained its rating at "Buy." The Danish pharmaceutical company's quarterly results were mixed, Jo Walton wrote in a study published Thursday./rob/bek/ajx

  Publication of the original study: May 7, 2025 / 7:20 p.m. / GMT

  First distribution of the original study: May 8, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 7, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" following its first-quarter results, with a price target of 620 Danish kroner. The pharmaceutical company met sales expectations, although Wegovy revenues were slightly below expectations, Florent Cespedes wrote in a report released Wednesday. Earnings developed better than expected. The company's reduction of its annual targets was not surprising./rob/mis/gl

  Publication of the original study: May 7, 2025 / 8:32 a.m. / UTC First distribution of the original study: May 7, 2025 / 8:32 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 7, 2025

  Jefferies leaves Novo Nordisk at 'underperform' - target 415 kroner

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its rating for Novo Nordisk at "underperform" with a price target of 415 Danish kroner. Overall, the Danish company's quarterly sales met expectations, Benjamin Jackson wrote on Wednesday. The Wegovy and Rybelsus drugs were below expectations, but thanks to Ozempic and insulins, the company was overall in line. Earnings were slightly better. However, the reduction in the annual targets is somewhat more significant than feared./rob/ag/gl

  Publication of the original study: May 7, 2025 / 2:32 a.m. / ET First distribution of the original study: May 7, 2025 / 2:32 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 2, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. Analyst Jo Walton evaluated prescription trends for weight-loss medications in a study published Friday. The market for these drugs has not seen much movement this week. In recent days, the focus has primarily been on market participants' struggle for new sales opportunities, for example, in direct sales to drugstores./tih/he

  Publication of the original study: May 2, 2025 / 3:08 p.m. / GMT First distribution of the original study: May 2, 2025 / 3:08 p.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 2, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyser) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner. The recently concluded distribution agreement with CVS Caremark for the weight-loss drug Wegovy is likely to result in higher discounts, but also likely higher sales, analyst Florent Cespedes wrote in a study released Friday. This move should help boost US prescription trends in the second half of the year.

  Publication of the original study: May 2, 2025 / 3:55 PM / UTC. First distribution of the original study: May 2, 2025 / 3:55 PM / UTC.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 2, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. The patient group for which the company will have preferential access to the weight-loss drug Wegovy thanks to the cooperation with CVS Health is larger than initially expected, analyst Jo Walton wrote in his follow-up commentary on Friday. In addition, there is probably no need to fear a price war with Eli Lilly./ag/ajx

  Publication of the original study: May 2, 2025 / 9:46 a.m. / GMT

  First distribution of the original study: May 2, 2025 / 9:46 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 30, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk ahead of first-quarter results, with a price target of DKK 750. Analyst Jo Walton wrote in a report released Wednesday that a downgrade to the outlook is widely expected and has been priced in. Investors should pay closer attention to signals regarding the future product portfolio and its competitiveness.

  Publication of the original study: April 30, 2025 / 1:55 PM / GMT. First distribution of the original study: April 30, 2025 / 1:55 PM / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 30, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1,000 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained Novo Nordisk's "Overweight" rating with a price target of 1,000 Danish kroner. Revenue is slightly below market estimates, while operating profit and earnings per share are within market estimates, analyst Richard Vosser wrote on Wednesday in an outlook on the pharmaceutical company's quarterly report./ajx/gl

  Publication of the original study: April 30, 2025 / 10:12 AM / BST First distribution of the original study: April 30, 2025 / 10:12 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 29, 2025

  Deutsche Bank maintains 'Buy' rating on Novo Nordisk - target 750 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Novo Nordisk at "Buy" with a price target of DKK 750 following expert discussions on obesity drugs. Reactions were mixed, wrote analyst Emmanuel Papadakis in a study released Tuesday. In some cases, they confirmed his constructive assessment of Novo Nordisk's prospects, but at other times in a way that contradicts common sense./edh/ck

  Publication of the original study: April 29, 2025 / Time not specified in the study / CEST

  First distribution of the original study: April 29, 2025 / 8:01 a.m. / CEST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 28, 2025

  Goldman maintains Novo Nordisk at 'Buy' - target 825 crowns

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Novo Nordisk with a price target of 825 Danish kroner. European pharmaceutical companies have a significant dollar share of their revenues, analyst James Quigley wrote on Monday during the earnings season. He has now adjusted his estimates for 2025 and 2026 to reflect the recent dollar weakness and highlighted the risks to the market consensus. At Novo, he sees a need for an adjustment of around 5 percent for operating profit./ag/la

  Publication of the original study: April 28, 2025 / 5:02 a.m. / BST First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 25, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of DKK 750. Rival Eli Lilly continues to grow strongly in the weight-loss drug market, analyst Jo Walton wrote in a study released Monday. Prescriptions for Novo Nordisk products, on the other hand, are stagnating, which is likely to disappoint investors./bek/nas

  Publication of the original study: April 25, 2025 / 11:02 AM / GMT

  First distribution of the original study: April 25, 2025 / 11:02 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 17, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner. In a quick assessment released Thursday, analyst Florent Cespedes cited positive study data from US pharmaceutical company Eli Lilly on its weight-loss pill Orforglipron for diabetes. According to him, this creates a "serious competitor" for the Danes./ck/men

  Publication of the original study: April 17, 2025 / 1:34 PM / UTC

  First distribution of the original study: April 17, 2025 / 1:34 PM / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 17, 2025

  Jefferies maintains Novo Nordisk's 'underperform' rating

  NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its rating for Novo Nordisk at "underperform" with a price target of 415 Danish kroner. The positive results of Eli Lilly's oral GLP-1 in diabetics appear competitive with the Danish company's injectable Ozempic, analyst Benjamin Jackson wrote in a report released Thursday. Concerns about potential obstacles to Novo's GLP-1 growth are likely to intensify.

  Publication of the original study: April 17, 2025 / 11:05 AM / ET. First distribution of the original study: April 17, 2025 / 11:05 AM / ET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 17, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1,000 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,000 Danish kroner. Analyst Richard Vosser cited study data on the weight-loss pill Orforglipron from US pharmaceutical company Eli Lilly on Thursday. He said these studies confirmed the expected weight loss, which is broadly consistent with the injectable products Ozempic from Novo Nordisk and Mounjaro from Eli Lilly. The data does show how competitive Orforglipron is. However, taking the pill has potentially led to higher rates of diarrhea, which could reduce the competitive pressure on Novo.

  Publication of the original study: April 17, 2025 / 1:37 PM / BST First distribution of the original study: April 17, 2025 / 1:37 PM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 15, 2025

  Barclays lowers target for Novo Nordisk to 700 kroner; 'Overweight'

  LONDON (dpa-AFX Analyst) - British investment bank Barclays has lowered its price target for Novo Nordisk from 900 to 700 Danish kroner, but maintained its "overweight" rating. Analyst Emily Field believes a recovery in prescriptions for weight-loss pills in the US is unlikely before the summer, according to a commentary released Wednesday. The Danes' currency-adjusted revenue growth is currently at the bottom of their full-year target range, they wrote./ag/edh

  Publication of the original study: April 15, 2025 / 8:31 p.m. / GMT

  First distribution of the original study: April 16, 2025 / 3:00 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 7, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. The Danish pharmaceutical company has recently lagged behind Eli Lilly in growth with weight-loss drugs, wrote analyst Jo Walton in a study published Tuesday./bek/zb

  Publication of the original study: April 7, 2025 / 1:01 p.m. / GMT

  First distribution of the original study: April 7, 2025 / 1:01 p.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 7, 2025

  Deutsche Bank Research lowers target for Novo Nordisk - 'Buy'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research lowered its price target for Novo Nordisk from 900 to 750 Danish kroner, but maintained its "Buy" rating. Thanks to their defensive profile and initial exemption from the new US tariffs, the European pharmaceutical stocks have withstood the recent market turmoil, wrote analyst Emmanuel Papadakis in an outlook on the industry's first-quarter results released Monday. However, he has little confidence that this will remain the case in the long term./gl/nas

  Publication of the original study: April 7, 2025 / 8:00 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CEST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 4, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. Analyst Jo Walton examined Google search results for weight-loss injections from Novo and competitor Eli Lilly in a study released Monday. Since the end of September last year, there have been more searches outside the US for the American drug Mounjaro than for the Danish drug Wegovy, even though Novo's marketing expenditures are higher than those of Eli Lilly./la/ck

  Publication of the original study: April 4, 2025 / 7:57 PM / GMT

  First distribution of the original study: April 4, 2025 / 7:57 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 3, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner. Analyst Florent Cespedes, in an industry report released Thursday, viewed the exemption of pharmaceutical products from the comprehensive US tariffs as a positive factor. This is positive for sentiment, after recent fears about the consequences of possible import duties had weighed on investor sentiment. The consequences for the companies' non-pharmaceutical products should be manageable in the meantime./mis/men

  Publication of the original study: April 3, 2025 / 7:39 a.m. / UTC

  First distribution of the original study: April 3, 2025 / 7:39 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 2, 2025

  Goldman maintains Novo Nordisk at 'Buy' - target 822 crowns

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained a "buy" rating on Novo Nordisk with a price target of 822 Danish kroner. In the short term, the pharmaceutical company's share price remains tied to the prescription trends for the GLP-1 weight-loss medication published last Friday, analyst James Quigley wrote in an assessment published Thursday. He does not expect a recovery in momentum in the US. A potential disappointment with the key drug Ozempic in the first quarter could lead to a reduction in the annual targets. In the long term, however, he sees upside potential in this area, which is underestimated by the market./gl/ag

  Publication of the original study: April 2, 2025 / 7:00 a.m. / BST First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 2, 2025

  Jefferies lowers target for Novo Nordisk - 'Underperform'

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has lowered its price target for Novo Nordisk from 450 to 415 Danish kroner and maintained the rating at "underperform." Looking ahead to the quarterly report in early May, analyst Lucy Codrington sees slight risks of disappointment in the sales and operating earnings consensus. The Danes could lower their full-year targets, she wrote in her outlook on the report published Thursday. However, this is already being anticipated by the market. The focus remains on GLP-1 weight loss products. Neither Ozempic nor Wegovy have seen any noticeable gains in the US so far in 2025. With its price target, Codrington is reducing the valuation relative to the industry./ag/gl

  Publication of the original study: April 2, 2025 / 5:45 PM / ET. First distribution of the original study: April 2, 2025 / 7:00 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 31, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. In a study published Monday, analyst Jo Walton pointed to current prescription trends in the US for the active ingredient GLP-1, which is said to suppress appetite./ck/he

  Publication of the original study: March 31, 2025 / 2:08 p.m. / GMT First distribution of the original study: March 31, 2025 / 2:08 p.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 28, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyser) - The Swiss major bank UBS has maintained its rating for Novo Nordisk at "Buy" with a price target of 750 Danish kroner in view of current prescription trends for weight loss drugs (GLP-1). There is growth for competitor Eli Lilly's Zepbound drug, while others are experiencing a decline, wrote analyst Jo Walton in a study released Friday./tih/he

  Publication of the original study: March 28, 2025 / 1:42 PM / GMT

  First distribution of the original study: March 28, 2025 / 1:42 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 27, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1,000 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" ahead of first-quarter results, with a price target of 1,000 Danish kroner. The Danish pharmaceutical company is likely to confirm its sales and profit targets, analyst Richard Vosser wrote in an assessment released Friday. Given the concerns previously expressed regarding the outlook and the weak start to the year for the diabetes and diet drug Wegovy in the US, this could reassure investors./la/mis/mis

  Publication of the original study: March 27, 2025 / 8:27 PM / GMT. First distribution of the original study: March 28, 2025 / 12:15 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 27, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. The more than 20 percent share price decline this year is primarily a reflection of current concerns about demand for the Danish pharmaceutical company's weight-loss drug Wegovy, wrote analyst Jo Walton in his commentary published Friday. Another key topic is competitor Eli Lilly's study on the orally administered GLP1 weight-loss drug orforglipron. The key factor here is tolerability compared to Novo's semaglutide./edh/ag

  Publication of the original study: March 27, 2025 / 7:23 PM / GMT

  First distribution of the original study: March 28, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 21, 2025

  Berenberg lowers target for Novo Nordisk to 610 kroner - 'Hold'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Novo Nordisk from 725 to 610 Danish kroner, but maintained its "Hold" rating. The pharmaceutical company's latest data on the weight-loss drug Cagrisema were disappointing, wrote analyst Kerry Holford in her commentary published on Monday. Continued discussions with obesity specialists also suggest adjustments to expectations for this market segment./bek/ag

  Publication of the original study: March 21, 2025 / 5:56 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 21, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. Analyst Jo Walton cited prescription trends for the pharmaceutical company's GLP-1 weight-loss drug Wegovy in the US market on Friday. It is now clear that growth there in the first quarter was more disappointing than expected. Large-scale advertising campaigns may not have been successful, and Novo Nordisk lost market share among new patients./la/gl

  Publication of the original study: March 21, 2025 / 12:36 / GMT First distribution of the original study: March 21, 2025 / 12:36 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 17, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyser) - The Swiss major bank UBS has maintained Novo Nordisk's "Buy" rating with a price target of 750 Danish kroner. The latest data showed that first-time prescription trends for the pharmaceutical company's GLP-1 weight-loss drug Wegovy in the US market declined in the week ending March 7, analyst Jo Walton wrote in an initial response on Monday./gl/mis

  Publication of the original study: March 17, 2025 / 4:54 PM / GMT First distribution of the original study: March 17, 2025 / 4:54 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 14, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. Analyst Jo Walton examined current prescription trends for weight-loss medication (GLP-1) in a study published Friday. There are positive signs, but Novo Nordisk investors would like more clarity. The active ingredient semaglutide has now been removed from the US FDA's scarcity list, so investors are waiting for an improvement in the trend./tih/gl

  Publication of the original study: March 14, 2025 / 12:25 / GMT First distribution of the original study: March 14, 2025 / 12:25 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 11, 2025

  Deutsche Bank maintains Novo Nordisk's 'Buy' rating - target 900 kroner

  FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research has maintained its rating for Novo Nordisk at "Buy" with a price target of 900 Danish kroner following new study data on the weight loss drug Cagrisema. In summary, the headlines are a "non-event," wrote analyst Emmanuel Papadakis in a study released Tuesday./tih/edh

  Publication of the original study: March 11, 2025 / Time not specified in the study / CET

  First distribution of the original study: March 11, 2025 / 7:50 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 11, 2025

  Jefferies lowers target for Novo Nordisk - 'Underperform'

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has lowered its price target for Novo Nordisk from 515 to 450 Danish kroner and maintained its rating at "underperform." There is likely no "grace period" for the weight-loss drug Cagrisema, which disappointed in the "Redefine 2" study, wrote analyst Benjamin Jackson in a report released Wednesday. He referred to the upcoming announcements regarding competitor Eli Lilly's oral GLP-1, skepticism regarding positive effects due to the end of the legality of compounded preparations, and the potential risks posed by price negotiations in the US./ck/tih

  Publication of the original study: March 11, 2025 / 6:20 PM / ET

  First distribution of the original study: March 11, 2025 / 8:01 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 10, 2025

  Goldman maintains Novo Nordisk at 'Buy' - target 890 crowns

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Novo Nordisk with a price target of 890 Danish kroner. The results of the REDEFINE-2 study with CagriSema for obesity met expectations, analyst James Quigley wrote on Monday afternoon./ag/gl

  Publication of the original study: March 10, 2025 / 12:22 / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 10, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk, based on GLP-1 market data from the analytics firm Iqvia, with a price target of DKK 750. There are positive signs in the appetite suppressant market, but investors are demanding more, analyst Jo Walton wrote in a report released Monday. He continues to expect an improvement in prescription trends over the course of the year./tih/ck

  Publication of the original study: March 10, 2025 / 12:48 PM / GMT

  First distribution of the original study: March 10, 2025 / 12:48 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 10, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyser) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of DKK 620 following study data on the drug Cagrisema. The results were mixed regarding weight loss and dosability, wrote analyst Florent Cespedes in a study released Monday. He therefore believes it is still too early to assess Novo shares more positively./tih/la

  Publication of the original study: March 10, 2025 / 1:05 PM / UTC. First distribution of the original study: March 10, 2025 / 1:05 PM / UTC.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 10, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1,000 kroner

  NEW YORK (dpa-AFX Analyst) - Following study data on the drug CagriSema, US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,000 Danish kroner. The weight-loss drug remains on par with Zepbound from US competitor Eli Lilly, analyst Richard Vosser wrote in a study released Monday. However, hopes that more patients could be administered the maximum dose were likely somewhat dashed. However, this does not justify the share price decline following the announcements./tih/ck

  Publication of the original study: March 10, 2025 / 11:57 AM / GMT

  First distribution of the original study: March 10, 2025 / 11:57 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 10, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its "Market-Perform" rating on Novo Nordisk with a price target of 620 Danish kroner. Analyst Courtney Breen noted in a study released Monday that the US is moving toward a ban on the production of appetite-suppressant GLP-1 combination preparations. This could soon result in many patients losing access to such medications. Companies like Eli Lilly and Novo Nordisk are seizing this opportunity to retain self-paying patients. To this end, both have established offerings aimed directly at the end consumer. She believes Eli Lilly has the upper hand./ck/tih

  Publication of the original study: March 10, 2025 / 10:52 / UTC

  First distribution of the original study: March 10, 2025 / 10:52 / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 7, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. The prescription trend for GLP-1 weight loss drugs has recently recovered strongly, analyst Jo Walton wrote on Friday, referring to the weekly US data. These are the strongest figures of the current year. However, Walton isn't yet talking about a trend reversal./ag/gl

  Publication of the original study: March 7, 2025 / 11:29 AM / GMT First distribution of the original study: March 7, 2025 / 11:29 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 3, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. The Danes have recently performed weaker than Eli Lilly in terms of new prescriptions for GLP-1 weight loss products, analyst Jo Walton wrote on Monday after analyzing weekly data. Overall, the development remains slightly disappointing./ag/la

  Publication of the original study: March 3, 2025 / 11:59 AM / GMT

  First distribution of the original study: March 3, 2025 / 11:59 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 26, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1,000 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,000 Danish kroner. Analyst Richard Vosser, in a report released Wednesday, pointed to data from competitor Eli Lilly on the diabetes and obesity pill orforglipron, which is due in the second quarter. He assumes that results confirming efficacy consistent with Novo Nordisk's weight-loss injections Wegovy and Ozempic, as well as the oral semaglutide, are likely to exert only limited additional pressure on Novo Nordisk./ck/tih

  Publication of the original study: February 26, 2025 / 05:22 / GMT

  First distribution of the original study: February 26, 2025 / 05:22 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 25, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained a "Market-Perform" rating on Novo Nordisk with a price target of 620 Danish kroner. The Danish company's shares gained after it emerged that other pharmaceutical companies were no longer selling products in the US that imitated the weight-loss drug Wegovy, analyst Florent Cespedes wrote in a report released Tuesday. This news, which is positive overall, follows the unsurprising announcement last week that Wegovy is no longer on the US Food and Drug Administration's (FDA) list of drugs in short supply.

  Publication of the original study: February 25, 2025 / 12:23 / UTC. First distribution of the original study: February 25, 2025 / 12:23 / UTC.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 24, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. Analyst Jo Walton reviewed data for the week ending February 14 from healthcare IT company Iqvia on the starter doses of GLP-1 to treat obesity in the US market, according to a study released Monday. Total new prescriptions at Novo Nordisk increased by 1.9 percent week-on-week, compared to an increase of 14.7 percent at Eli Lilly./ck/bek

  Publication of the original study: February 24, 2025 / 12:19 / GMT

  First distribution of the original study: February 24, 2025 / 12:19 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 20, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 620 Danish kroner. In an industry report released Thursday, analyst Florent Cespedes refers to the US tariff threats, which also affect pharmaceutical products. According to the World Trade Organization (WTO), pharmaceutical products are considered essential goods and are therefore exempt from tariffs, the expert stated. However, potential collateral damage should be considered. In return, European pharmaceutical companies could invest less money in research in the US, which could reduce US tax revenues in the long term. Furthermore, many US companies produce in Ireland and would therefore also be affected by tariffs. All in all, it remains unclear whether tariffs will even be imposed./mis/edh

  Publication of the original study: February 20, 2025 / 8:54 a.m. / UTC

  First distribution of the original study: February 20, 2025 / 8:54 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 17, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. The number of new prescriptions for the Danish company's GLP1 weight-loss products rose 3.6 percent in the week ending January 7, more than that of competitor Eli Lilly, analyst Jo Walton wrote on Monday. Overall, the data points to continued growth, but does not show any acceleration./ag/tih

  Publication of the original study: February 17, 2025 / 11:31 AM / GMT

  First distribution of the original study: February 17, 2025 / 11:31 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 17, 2025

  Deutsche Bank maintains Novo Nordisk's 'Buy' rating - target 900 kroner

  FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research has maintained its rating for Novo Nordisk at "Buy" with a price target of 900 Danish kroner. Although the approval of the diabetes and weight-loss drug Ozempic has also barely been registered as a drug for chronic kidney disease (CKD), analyst Emmanuel Papadakis considers this a modest success for the pharmaceutical company, wrote in his commentary published on Monday./edh/ag

  Publication of the original study: February 17, 2025 / 8:05 a.m. / CET

  First dissemination of the original study: February 17, 2025 / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 12, 2025

  Deutsche Bank maintains Novo Nordisk's 'Buy' rating - target 900 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Novo Nordisk with a price target of DKK 900. Analyst Emmanuel Papadakis gave Novo Nordisk a positive rating in a study released Wednesday, based on a survey of 100 US physicians on a treatment for non-alcoholic fatty liver disease. If the Phase III data are convincing, the drug could be quickly introduced into clinical practice./bek/tih

  Publication of the original study: February 12, 2025 / Time not specified in the study / CET

  First distribution of the original study: February 12, 2025 / 8:00 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 11, 2025

  Bernstein raises target for Novo Nordisk - 'Market-Perform'

  NEW YORK (dpa-AFX Analyser) - The US analyst firm Bernstein Research has raised its price target for Novo Nordisk from 600 to 620 Danish kroner following an investor event and left the rating at "Market-Perform". Following the disappointing Phase III trial data for the next-generation obesity product CagriSema in December, management has announced further details on the positioning of the drug in the pharmaceutical company's active ingredient portfolio, wrote analyst Florent Cespedes in a study published Tuesday./edh/he

  Publication of the original study: February 11, 2025 / 6:32 p.m. / UTC

  First distribution of the original study: February 11, 2025 / 6:32 p.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 10, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. New prescriptions for the weight-loss drug Wegovy increased by 9.4 percent in the last week of January compared to the previous week, analyst Jo Walton wrote in a study released Monday. Initial treatments with the drug Zepbound, also a weight-loss medication, increased even more sharply week-on-week./bek/tih

  Publication of the original study: February 10, 2025 / 00:07 / GMT

  First distribution of the original study: February 10, 2025 / 00:07 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 10, 2025

  Deutsche Bank maintains Novo Nordisk's 'Buy' rating - target 900 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Novo Nordisk following the release of its quarterly results, with a price target of DKK 900. Analyst Emmanuel Papadakis updated his assessment of the pharmaceutical company in a study published on Monday. He cited its strong quarterly figures and equally solid growth outlook, which investors had feared was at risk./ck/mis

  Publication of the original study: February 10, 2025 / Time not specified in the study / CET

  First distribution of the original study: February 10, 2025 / 8:05 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 10, 2025

  Goldman raises target for Novo Nordisk to 890 kroner - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs raised its price target for Novo Nordisk from 875 to 890 Danish kroner and maintained its "Buy" rating. Analyst James Quigley raised his earnings estimates for the Danish company in his review of the interim report published on Monday. He expects strong growth for the weight-loss injection semaglutide, and the US story of weight-loss pills is also becoming more concrete./ag/mis

  Publication of the original study: February 10, 2025 / 5:02 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 7, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Following a corporate event on the company's latest annual results, Swiss bank UBS maintained its "Buy" rating on Novo Nordisk with a price target of 750 Danish kroner. Management expressed satisfaction with the latest study results for the weight-loss products CagriSema and Amycretin, among other things, analyst Jo Walton wrote in an assessment released Friday. Previously, investors had been confused by some of the results on CagriSema, which the pharmaceutical company presented alongside its financial figures./gl/mis

  Publication of the original study: February 7, 2025 / 00:15 / GMT First distribution of the original study: February 7, 2025 / 00:15 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 5, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. The slimming injection manufacturer's sales and operating results were significantly better than market expectations, analyst Jo Walton wrote in his review on Wednesday evening. The conference call focused on initial data from the REDEFINE-1 study./edh/ag

  Publication of the original study: February 5, 2025 / 10:57 PM / GMT

  First distribution of the original study: February 5, 2025 / 10:57 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 5, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 600 Danish kroner. The Danish company performed better than expected, boosted by one-off effects, wrote analyst Florent Cespedes on Wednesday in an initial reaction to the pharmaceutical company's quarterly figures. The outlook for 2025 provides optimism./ajx/ag

  Publication of the original study: February 5, 2025 / 8:40 a.m. / UTC First distribution of the original study: February 5, 2025 / 8:41 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 5, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. The fourth quarter was strong, analyst Jo Walton wrote on Wednesday after an initial analysis of the figures. The Danes thus demonstrated solid growth in the area of GLP-1 diabetes and weight-loss products./ag/ajx

  Publication of the original study: February 5, 2025 / 8:05 a.m. / GMT

  First distribution of the original study: February 5, 2025 / 8:05 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 5, 2025

  Goldman maintains Novo Nordisk at 'Buy' - target 875 crowns

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Novo Nordisk with a price target of 875 Danish kroner. Analyst James Quigley attested to the pharmaceutical company's solid results and solid targets for 2025 on Wednesday following its quarterly report./ag/ajx

  Publication of the original study: February 5, 2025 / 7:42 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 5, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,050 Danish kroner. The Danes' targets for 2025 leave the consensus with considerable room for improvement, analyst Richard Vosser wrote on Wednesday after the results. He expects a very positive price reaction./ag/ajx

  Publication of the original study: February 5, 2025 / 7:44 a.m. / GMT

  First distribution of the original study: / / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 5, 2025

  Jefferies leaves Novo Nordisk at 'underperform' - target 515 kroner

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its rating for Novo Nordisk at "underperform" with a price target of 515 Danish kroner. The Danish company exceeded expectations in terms of sales of its insulin medications and profit in the fourth quarter, analyst Peter Welford wrote on Wednesday morning. The expected outlook still leaves room for improvement./ag/ajx

  Publication of the original study: February 5, 2025 / 2:15 a.m. / ET

  First distribution of the original study: February 5, 2025 / 2:15 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 3, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of DKK 750. Analyst Jo Walton evaluated weekly data on first prescriptions for GLP-1 weight-loss drugs in a study released Monday. Despite a public holiday the previous week, the trend in first doses remained strong.

  Publication of the original study: February 3, 2025 / 12:09 PM / GMT. First distribution of the original study: February 3, 2025 / 12:09 PM / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 29, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,050 Danish kroner. Analyst Richard Vosser drew a comparison on Wednesday with the recently published market consensus for the fourth quarter. Revenue is one percent higher at approximately 82.6 billion crowns, and operating profit is two percent higher at just over 34.1 billion crowns./ag/edh

  Publication of the original study: January 29, 2025 / 9:22 a.m. / GMT

  First distribution of the original study: January 29, 2025 / 9:22 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 27, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Buy" with a price target of 750 Danish kroner in light of recent prescription trends for weight-loss drugs in the US. Analyst Jo Walton wrote this in a study published on Tuesday./ajx/tih

  Publication of the original study: January 27, 2025 / 11:45 / GMT

  First distribution of the original study: January 27, 2025 / 11:45 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 24, 2025

  Deutsche Bank maintains Novo Nordisk's 'Buy' rating - target 900 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Novo Nordisk at "Buy" with a price target of DKK 900 following news about the obesity-promoting drug Amycretin. Analyst Emmanuel Papadakis wrote in a report released Monday that he had expected the relevant data to be released upon the company's quarterly results. Overall, he considers them "very encouraging."/ck/mis

  Publication of the original study: Date not specified in study / Time not specified in study / CET

  First distribution of the original study: January 27, 2025 / 8:10 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 24, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of DKK 750. Market growth for GLP-1 drugs for people with weight problems accelerated in the US in the week ending January 17, but the Lilly Group continues to lead the field, analyst Jo Walton wrote in a report released Friday. Initial study data on Novo Nordisk's weight-loss drug Amycretin have been strong, the expert emphasized./ajx/he

  Publication of the original study: January 24, 2025 / 1:10 p.m. / GMT First distribution of the original study: January 24, 2025 / 1:10 p.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 24, 2025

  Goldman maintains Novo Nordisk at 'Buy' - target 875 crowns

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Novo Nordisk with a price target of 875 Danish kroner. Analyst James Quigley responded positively to the study data on the weight-loss drug Amycretin on Friday. The achieved weight loss raises hopes for a "best-in-class profile." /ag/nas

  Publication of the original study: January 24, 2025 / 11:39 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 24, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" following study data on the weight-loss drug Amycretin, with a price target of DKK 1,050. The drug demonstrates a strong and competitive efficacy profile, analyst Richard Vosser wrote on Friday. He pointed to 22 percent weight loss with a 36-week 20-mg dose. At a reduced dose of 5 mg over 28 weeks, the drug is similarly effective to Eli Lilly's Zepbound./tih/ag

  Publication of the original study: January 24, 2025 / 12:22 / GMT

  First distribution of the original study: January 24, 2025 / 12:22 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 24, 2025

  Jefferies maintains Novo Nordisk's 'underperform' rating

  NEW YORK (dpa-AFX Analyser) - The analyst firm Jefferies has maintained its rating for Novo Nordisk at "underperform" with a price target of 515 Danish kroner. After disappointing initial data, the data from the Redefine 2 study are unlikely to be sufficient to improve investor sentiment regarding the weight-loss drug Cagrisema, wrote analyst Peter Welford in a study released Friday./mis/nas

  Publication of the original study: January 24, 2025 / 7:01 a.m. / ET

  First distribution of the original study: January 24, 2025 / 7:00 p.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 20, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyser) - The Swiss major bank UBS has maintained its rating for Novo Nordisk at "Buy" with a price target of 750 Danish kroner. Prescriptions for competitor Eli Lilly's weight-loss injection Zepbound recovered more strongly after the Christmas season than those for Novo's Wegovy, wrote analyst Jo Walton in his commentary on Monday afternoon./ag/ck

  Publication of the original study: January 20, 2025 / 1:04 PM / GMT

  First distribution of the original study: January 20, 2025 / 1:04 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 17, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 600 Danish kroner. The announcement by a US regulator that it may enter into price negotiations with the pharmaceutical company for its weight-loss drug semaglutide is likely to put downward pressure on prices, analyst Florent Cespedes wrote in a study published Friday. Nevertheless, the Danish company's earnings outlook remains strong. Referring to a successful study on a higher dose of semaglutide, the expert wrote: The higher the dose, the better, apparently, although side effects are likely to increase./mis/stw

  Publication of the original study: January 17, 2025 / 6:10 p.m. / UTC

  First distribution of the original study: January 17, 2025 / 6:10 p.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 17, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of DKK 1,050 following study data on high-dose Wegovy. The weight loss in the high dose is competitive, analyst Richard Vosser wrote in a study released Friday. This gives the Danish pharmaceutical company more options in its weight-loss drug business./mis/zb

  Publication of the original study: January 17, 2025 / 2:30 PM / GMT

  First distribution of the original study: January 17, 2025 / / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 17, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Buy" with a price target of 750 Danish kroner following study data on the high-dose weight-loss drug Wegovy. These results were positive, wrote analyst Jo Walton in a study published Friday. Compared to the lower dose, greater weight loss was observed./la/mis

  Publication of the original study: January 17, 2025 / 2:08 PM / GMT

  First distribution of the original study: January 17, 2025 / 2:08 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 15, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. Analyst Jo Walton wrote in a report released Thursday that he believes the recent share price reaction to the Phase III results of the CagriSema study is exaggerated. He therefore sees an attractive entry point and continues to consider his upgrade of the diabetes specialist's share to "Buy" on January 8th to be justified./ck/nas

  Publication of the original study: January 15, 2025 / 6:52 PM / GMT

  First distribution of the original study: January 15, 2025 / 6:52 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 14, 2025

  Bernstein maintains Novo Nordisk at 'Market-Perform'

  NEW YORK (dpa-AFX Analyser) - The US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "Market-Perform" with a price target of 600 Danish kroner following statements by Eli Lilly regarding the situation in the US market for weight-loss drugs. The statement that demand was somewhat less dynamic than expected in the final quarter of 2024 contrasts with the Danes' optimistic statements about their drug Wegovy, wrote analyst Florent Cespedes in a study published Wednesday./bek/mis

  Publication of the original study: January 14, 2025 / 5:50 p.m. / UTC

  First distribution of the original study: January 15, 2025 / 5:50 p.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 13, 2025

  UBS maintains Novo Nordisk at 'Buy' - target 750 crowns

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Novo Nordisk with a price target of 750 Danish kroner. As expected, prescription trends for GLP-1 drugs in the US slowed somewhat over the Christmas holidays, wrote analyst Jo Walton in a study published Monday./ajx/he

  Publication of the original study: January 13, 2025 / 1:02 PM / GMT First distribution of the original study: January 13, 2025 / 1:02 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 10, 2025

  Goldman lowers target for Novo Nordisk to 875 kroner - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Novo Nordisk from 1,025 to 875 Danish kroner, but maintained its "Buy" rating. The pharmaceutical stock's negative price reaction to disappointing Phase III trial results for its weight-loss drug Cagrisema was exaggerated and offers an attractive long-term buying opportunity, analyst James Quigley wrote in an assessment released Friday. Although he has significantly lowered his sales estimates for the Danish company's corresponding drugs, he still sees significant upside potential.

  Publication of the original study: January 10, 2025 / 5:01 a.m. / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 7, 2025

  UBS upgrades Novo Nordisk to 'Buy' - lowers target to 750 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has upgraded Novo Nordisk from "Neutral" to "Buy," but lowered its price target from 1,100 to 750 Danish kroner. The stock sell-off following disappointing Phase III trial data for the weight-loss drug Cagrisema is excessive and offers an attractive entry opportunity, analyst Jo Walton wrote in a report published Wednesday. He lowered his earnings (EPS) estimates due to the data. However, the Danish pharmaceutical company remains the most attractive growth story in Europe in this area and is well positioned to continue to benefit from the high demand, the expert emphasized.

  Publication of the original study: January 7, 2025 / 10:58 PM / GMT. First distribution of the original study: January 7, 2025 / 10:58 PM / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 6, 2025

  Berenberg maintains Novo Nordisk on 'Hold' - target 725 kroner

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Hold" rating for Novo Nordisk with a price target of 725 Danish kroner. With regard to the industry, company-specific pressures in China are likely to ease in the new year, and valuation pressure on companies active in the US vaccine market is also likely to ease, wrote analyst Luisa Hector in an industry study published Tuesday. The latter is because the Trump administration is unlikely to be able to implement all of its election campaign plans. In addition, drugs and drug candidates for obesity remained an important topic./mis/zb

  Publication of the original study: January 6, 2025 / 6:03 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 6, 2025

  Bernstein upgrades Novo Nordisk to 'Market-Perform'

  NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has upgraded Novo Nordisk from "Underperform" to "Market-Perform" and raised its price target from 560 to 600 Danish kroner. Analyst Florent Cespedes initially noted in a study released Monday that the shares have fallen 40 percent since their record high in June 2024. This development has made the valuation more attractive again, especially since there are still growth opportunities in the obesity sector.

  Publication of the original study: January 6, 2025 / 3:53 PM / UTC. First distribution of the original study: January 6, 2025 / 4:47 PM / UTC.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 3, 2025

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" ahead of fourth-quarter results, with a price target of 1,050 Danish kroner. The pharmaceutical company appears to have performed solidly, analyst Richard Vosser wrote in a report released Monday. The targets for the year just begun are also expected to be solid./la/zb

  Publication of the original study: January 3, 2025 / 5:43 PM / GMT. First distribution of the original study: January 6, 2025 / 12:15 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 3, 2025

  Berenberg lowers target for Novo Nordisk to 725 kroner - 'Hold'

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Novo Nordisk from 975 to 725 Danish kroner and maintained its "Hold" rating. Analyst Kerry Holford justified the target reduction in a study released Monday with disappointing study data on the weight-loss drug Cagrisema. The weight loss fell short of investors' expectations./mis/bek

  Publication of the original study: January 3, 2025 / 5:30 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 3, 2025

  Jefferies lowers Novo Nordisk target to 515 kroner - 'Underperform'

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has lowered its price target for Novo Nordisk from 575 to 515 Danish kroner and maintained its rating at "underperform." Analyst Peter Welford, in a report released Monday, noted disappointing study data for the drug Cagrisema, which is used to treat obesity. He expects a one-year delay to the market launch in 2027 and simultaneously reduced his forecast for the drug's maximum achievable sales. The consensus estimates for Cagrisema would likely have to fall even further./bek/mis

  Publication of the original study: January 3, 2025 / 12:02 PM / ET

  First distribution of the original study: January 5, 2025 / 7:00 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 23, 2024

  Barclays lowers target for Novo Nordisk - 'Overweight'

  LONDON (dpa-AFX Analyst) - British investment bank Barclays has lowered its price target for Novo Nordisk from 1,050 to 900 Danish kroner, but maintained its rating at "Overweight." Despite the latest study results on the weight-loss drug Cagrisema, analyst Emily Field continues to view it as a promising drug, according to a commentary published on Monday.

  Publication of the original study: December 23, 2024 / 3:33 a.m. / GMT

  First distribution of the original study: December 23, 2024 / 4:00 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 20, 2024

  Bernstein maintains Novo Nordisk's 'underperform' rating

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "underperform" with a price target of 560 Danish kroner. Study results for the obesity drug Cagrisema were disappointing, analyst Florent Cespedes wrote in a report released Friday. The drug is not superior to Eli Lilly's competing product Zepbound. Novo Nordisk, he told him, attributed the disappointing results to the study protocol. Patients would have had the choice of either taking the lower dose to experience fewer side effects or taking the higher dose, which, while more effective, carries the risk of greater gastrointestinal side effects./la/mis

  Publication of the original study: December 20, 2024 / 2:24 PM / UTC First distribution of the original study: December 20, 2024 / 2:24 PM / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 20, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner. The weight-loss drug Cagrisema barely differentiated itself from Eli Lilly's competing product Zepbound in the study, analyst Jo Walton wrote on Friday in light of "massively disappointing data." Both the company itself and market players had expected a weight reduction of 25 percent, significantly higher than the 20.4 percent now shown in the overall group of all test subjects. Walton also sees negative signals for the promising drug Amycretin, which uses a similar approach. In the future, the focus is likely to be less on improved efficacy and more on the availability, tolerability, and convenience of oral administration./ag/mis

  Publication of the original study: December 20, 2024 / 12:33 / GMT

  First distribution of the original study: December 20, 2024 / 12:33 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 20, 2024

  Jefferies leaves Novo Nordisk at 'underperform' - study shock

  NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its rating for Novo Nordisk at "underperform" with a price target of 575 Danish kroner. The study data for the weight-loss drug Cagrisema are a shock, analyst Peter Welford wrote on Friday. The weight reduction results are disappointing, and safety concerns are also emerging. Welford's forecast for Cagrisema's peak sales of $7.5 billion is well below the consensus of well over $20 billion. He estimates the appropriate share price loss following the announcement at 10 to 15 percent./ag/ajx

  Publication of the original study: December 20, 2024 / 6:17 a.m. / ET

  First distribution of the original study: December 20, 2024 / 6:17 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 16, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner. The number of new prescriptions for weight-loss pills in the US continues to increase slightly, analyst Jo Walton wrote on Monday in his commentary on the latest weekly data through December 6./ag/mis

  Publication of the original study: December 16, 2024 / 11:58 / GMT

  First distribution of the original study: December 16, 2024 / 11:58 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 15, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,050 Danish kroner. The Danish company's shares are also on its "Analyst Focus List" and have been placed on "Positive Catalyst Watch." The acquisition of contract manufacturer Catalent will be completed in the coming days, analyst Richard Vosser wrote in his commentary published Monday. This is extremely positive for investor sentiment, as it is practically synonymous with the Danes' supply chain./ag/bek

  Publication of the original study: December 15, 2024 / 10:31 PM / GMT

  First distribution of the original study: December 16, 2024 / 2:14 AM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 12, 2024

  Deutsche Bank Research maintains Novo Nordisk's 'Buy' rating

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "Buy" rating on Novo Nordisk with a price target of 1,000 Danish kroner. Discussions with the pharmaceutical company have revealed few details on key business drivers, analyst Emmanuel Papadakis wrote in a commentary published Thursday. However, the overall tone was optimistic shortly before the release of key data on the weight-loss drug Cagrisema./gl/mis

  Publication of the original study: December 12, 2024 / 7:50 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 9, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner in light of recent prescription trends for weight-loss drugs in the US. Analyst Jo Walton wrote this in a report published on Monday./ajx/jha/

  Publication of the original report: December 9, 2024 / 3:06 PM / GMT

  First distribution of the original report: December 9, 2024 / 3:06 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 7, 2024

  Bernstein leaves Novo Nordisk at 'underperform' - target 560 crowns

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "underperform" with a price target of 560 Danish kroner. Weight-loss drug manufacturers such as the Danish company and Eli Lilly are not exactly focusing on China given existing capacity bottlenecks, analyst Rebecca Liang wrote in her assessment released Monday. Contrary to previous assumptions, a scenario in which local providers secure the lion's share of the market is also conceivable./ag/gl

  Publication of the original study: December 7, 2024 / 5:14 p.m. / UTC. First distribution of the original study: December 8, 2024 / 8:30 p.m. / UTC.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 4, 2024

  Bernstein leaves Novo Nordisk at 'underperform' - target 560 crowns

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained Novo Nordisk's "underperform" rating with a price target of DKK 560, in light of strong study data from competitor Eli Lilly. The US biotech company's obesity drug Zepbound is more effective than the Danish diabetes specialist's Wegovy, wrote analyst Florent Cespedes in a quick assessment published Wednesday. He added, however, that given the dual mechanism of action, Zepbound's greater efficacy is not surprising. Rather, he was surprised by the somewhat lower-than-expected effectiveness of Wegovy./ck/mis

  Publication of the original study: December 4, 2024 / 1:40 PM / UTC

  First distribution of the original study: December 4, 2024 / 1:40 PM / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 4, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,050 Danish kroner. The outcome of the comparative study of the weight-loss products Zepbound and Wegovy delivered exactly the expected results, analyst Richard Vosser wrote on Wednesday afternoon. The weak price reaction is therefore unjustified. Wegovy's prospects remain unchanged./ag/mne

  Publication of the original study: December 4, 2024 / 12:43 PM / GMT

  First distribution of the original study: December 4, 2024 / 12:43 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 2, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained Novo Nordisk's "Overweight" rating with a price target of 1,050 Danish kroner. The coming year is likely to be characterized by innovations from product pipelines for European pharmaceutical companies, given several important patent expiries, analyst Richard Vosser wrote in an outlook published Tuesday. His preferred industry giants are Novo Nordisk and AstraZeneca, and from the life sciences sector, Merck KGaA, among others. Novo Nordisk is also on the "Analyst Focus List" and has "Positive Catalyst Watch" status, with Vosser expressing his optimistic expectations for successful new products. However, he does not expect any success at Roche and little news at GSK./gl/ag

  Publication of the original study: December 2, 2024 / 8:11 p.m. / GMT. First distribution of the original study: December 3, 2024 / 12:15 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• December 2, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner. Although the weight-loss drug Wegovy is now readily available again, there is no noticeable increase in demand in the US, wrote analyst Jo Walton in his commentary published on Monday./ag/nas

  Publication of the original study: December 2, 2024 / 11:53 / GMT

  First distribution of the original study: December 2, 2024 / 11:53 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 29, 2024

  Jefferies maintains Novo Nordisk's 'underperform' rating

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has maintained its rating for Novo Nordisk at "underperform" with a price target of 575 Danish kroner. Phase III trial data for the combination drug CagriSema for diabetes and obesity are likely to be positive, wrote analyst Peter Welford in a study published Sunday. Nevertheless, market expectations regarding peak sales potential appear far too high. In addition, prices for GLP-1 drugs in the US are under pressure, and thus also margins, as production of such drugs is increasing. The expert therefore considers the market's medium-term profit expectations for the Danish pharmaceutical company to be too high./mis

  Publication of the original study: November 29, 2024 / 9:10 a.m. / ET

  First distribution of the original study: December 1, 2024 / 3:30 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 27, 2024

  Deutsche Bank Research maintains Novo Nordisk's 'Buy' rating

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Novo Nordisk with a price target of 1,000 Danish kroner. There are two pieces of slightly positive news for the Danes, wrote analyst Emmanuel Papadakis in his commentary published on Wednesday. This is, on the one hand, the prospect of extensive reimbursement for weight-loss therapy in the US, and, on the other hand, the long-awaited study data from Amgen on its drug AMG133./ag/tav

  Publication of the original study: November 27, 2024 / Time not specified in study / CET. First distribution of the original study: November 27, 2024 / 07:55 / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 26, 2024

  Goldman maintains Novo Nordisk at 'Buy' - target 1025 kroner

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Novo Nordisk with a price target of 1,025 Danish kroner. At first glance, the study data for the weight-loss drug from the American pharmaceutical company Amgen did not change its market assessment, analyst James Quigley wrote on Tuesday evening. The Danes would have a clear lead with Wegovy and CagriSema./ag/zb

  Publication of the original study: November 26, 2024 / 5:32 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 18, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyser) - Swiss bank UBS has left its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner following weekly data on the weight loss drug Wegovy. In a study released Monday, analyst Jo Walton noted a stagnation in the weight-loss drug Wegovy, reflecting prescription trends for new GLP-1 drugs (drugs with an appetite-suppressing effect)./ck/he

  Publication of the original study: November 18, 2024 / 12:17 / GMT. First distribution of the original study: November 18, 2024 / 12:17 / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 15, 2024

  Goldman maintains Novo Nordisk at 'Buy' - target 1025 kroner

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Novo Nordisk with a price target of 1,025 Danish kroner. The next key price driver for the Danish company's shares will be the efficacy data from the study with the combination drug CagriSema, wrote analyst James Quigley in his outlook published Friday. He expects publication by the end of November. The achieved weight loss should be over 25 percent - he expects 27 to 28 percent./ag/tih

  Publication of the original study: November 15, 2024 / 5:01 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 12, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyser) - UBS has left its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner following the major Swiss bank's in-house investor conference. Supply chain bottlenecks, the timing of new capacity, and progress on the planned acquisition of Catalent were the topics discussed, wrote analyst Jo Walton in a report released Wednesday./ajx/tih

  Publication of the original report: November 12, 2024 / 9:07 PM / GMT

  First distribution of the original report: November 12, 2024 / 9:07 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 11, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,050 Danish kroner ahead of new study data on the drug CagriSema. These should be positive, wrote analyst Richard Vosser in a report released Monday. He therefore added the pharmaceutical company's shares to a short-term recommendation list.

  Publication of the original study: November 11, 2024 / 12:19 / GMT First distribution of the original study: November 11, 2024 / 12:19 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 11, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "neutral" with a price target of 1,100 Danish kroner. The prescription trend for the weight-loss drug Wegovy continues to show a slight upward trend in the US, analyst Jo Walton wrote on Monday afternoon. Starting next week, the data is expected to pick up, following Wegovy's recent removal from the list of scarce drugs./ag/mis

  Publication of the original study: November 11, 2024 / 12:30 / GMT

  First distribution of the original study: November 11, 2024 / 12:30 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 11, 2024

  Goldman lowers target for Novo Nordisk to 1,025 kroner - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Novo Nordisk from 1,040 to 1,025 Danish kroner, but maintained its "Buy" rating. Analyst James Quigley adjusted his estimates in his commentary published Monday based on the third-quarter results. The confirmation of the 2024 growth target is positive, as it indicates a recovery in the final quarter and into 2025. Investors remain focused on the study with cagrilintide/semaglutide and the competition authorities' decision on the Catalent acquisition./ag/mis

  Publication of the original study: November 11, 2024 / 05:01 / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 7, 2024

  Barclays maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  LONDON (dpa-AFX Analyst) - British investment bank Barclays has maintained Novo Nordisk's "Overweight" rating with a price target of 1,050 Danish kroner. The market was likely extremely concerned before the quarterly results, so they should now provide some relief towards the end of the year, analyst Emily Field wrote Thursday evening. Until then, important price drivers include the completion of the Catalent acquisition and study data on the combination drug Cagrisema. Field lowered its estimates slightly, but now sees the stock at an attractive entry level./gl/ag

  Publication of the original study: November 7, 2024 / 8:20 p.m. / GMT. First distribution of the original study: November 8, 2024 / 4:00 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 7, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1,100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner following a round of analysts. The topic of discussion was the expected growth rate in 2025, wrote analyst Jo Walton in a study published Thursday. It maintained its growth forecast of 23 percent for 2025, while the market expects 20 percent./ajx/he

  Publication of the original study: November 7, 2024 / 5:37 PM / GMT. First distribution of the original study: November 7, 2024 / 5:37 PM / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 7, 2024

  Deutsche Bank lowers target for Novo Nordisk to 1,000 kroner - 'Buy'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has lowered its price target for Novo Nordisk from 1,100 to 1,000 Danish kroner following the recently published quarterly figures, but left the rating at "Buy". The pharmaceutical company's groundbreaking sales outlook for 2025 appears to be a relatively reassuring confirmation of current estimates, wrote analyst Emmanuel Papadakis in a study released Thursday./edh/gl

  Publication of the original study: November 7, 2024 / Time not specified in the study / CET. First distribution of the original study: November 7, 2024 / 8:05 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 7, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,050 Danish kroner. Based on current signals, expectations for the full year and 2025 appear less risky than previously, wrote analyst Richard Vosser in his commentary on the quarterly report published Thursday. For the remainder of the year, the focus will now be on study results, such as those for the weight-loss drug Wegovy at a higher dose./ag/gl

  Publication of the original study: November 7, 2024 / 1:59 a.m. / GMT First distribution of the original study: November 7, 2024 / 1:59 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner. In a conference call, the pharmaceutical company forecast growth in the high teens for 2025, but market estimates are at 20 percent and UBS's at 22 percent, analyst Jo Walton wrote in an assessment on Wednesday. The price reaction reflected the Danes' statements accordingly. The shares had significantly reduced their price gains on Wednesday after an initial very strong increase./ajx/he

  Publication of the original study: November 6, 2024 / 7:13 PM / GMT First distribution of the original study: November 6, 2024 / 7:13 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  Goldman maintains Novo Nordisk at 'Buy' - target 1040 kroner

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Novo Nordisk with a price target of 1,040 Danish kroner. The third quarter was solid, wrote analyst James Quigley on Wednesday morning after the company's results. Sales of the weight-loss drug Wegovy are encouraging./ag/zb

  Publication of the original study: November 6, 2024 / 7:49 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - JPMorgan has maintained Novo Nordisk's "Overweight" rating with a price target of 1,050 Danish kroner following its quarterly results. The stock is also on the US bank's "Analyst Focus List." According to a study released Wednesday, analyst Richard Vosser sees the pharmaceutical company's stock as being significantly supported by the positive performance of the weight-loss drug Wegovy and the narrowed outlook.

  Publication of the original study: November 6, 2024 / 8:01 a.m. / GMT First distribution of the original study: November 6, 2024 / 10:24 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "neutral" with a price target of 1,100 Danish kroner. In the "initial diagnosis," the figures are likely to be received positively by the market, wrote analyst Jo Walton on Wednesday morning. In particular, a significant reduction in the sales target was expected./ag/gl

  Publication of the original study: November 6, 2024 / 7:52 a.m. / GMT First distribution of the original study: November 6, 2024 / 7:52 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 6, 2024

  Jefferies maintains Novo Nordisk's 'underperform' rating

  NEW YORK (dpa-AFX Analyst) - Following third-quarter results, analyst Jefferies maintained its rating for Novo Nordisk at "underperform," with a price target of 575 Danish kroner. While the diabetes specialist's revenues missed expectations, earnings exceeded expectations, analyst Peter Welford wrote Wednesday morning. As expected, the forecasts for revenue and operating profit were narrowed around the midpoints. He sees the robust figures as a relief overall given the share's previous weakness./ck/ag

  Publication of the original study: November 6, 2024 / 2:19 a.m. / ET

  First distribution of the original study: November 6, 2024 / 2:19 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 4, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner. Prescriptions for the weight-loss drug Wegovy in the US continued to increase moderately, analyst Jo Walton wrote on Monday following the latest data./ag/gl

  Publication of the original study: November 4, 2024 / 11:47 a.m. / GMT First distribution of the original study: November 4, 2024 / 11:47 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 1, 2024

  Goldman maintains Novo Nordisk at 'Buy' - target 1040 kroner

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained a "buy" rating on Novo Nordisk with a price target of DKK 1,040 following news of semaglutide in a phase 3 trial for the treatment of metabolic dysfunction-associated fatty liver hepatitis (MASH). Analyst James Quigley called this a "positive development" in a report released Monday. This supports the use of the antidiabetic drug semaglutide as a basic therapy for MASH./ck/gl

  Publication of the original study: November 1, 2024 / 1:50 PM / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 1, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - JPMorgan has maintained Novo Nordisk's "Overweight" rating with a price target of 1,050 Danish kroner. The stock is also on the US bank's "Analyst Focus List." Positive Phase III data on the weight-loss drug Wegovy should boost its distribution and reimbursement by health insurance companies, wrote analyst Richard Vosser in a study published Friday.

  Publication of the original study: November 1, 2024 / 2:14 PM / GMT. First distribution of the original study: November 1, 2024 / 2:28 PM / GMT.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 31, 2024

  Deutsche Bank Research maintains Novo Nordisk's 'Buy' rating

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "Buy" rating on Novo Nordisk with a price target of 1,100 Danish kroner. Although he has become accustomed to volatile share prices at the pharmaceutical company, the recent 10 percent intraday price fluctuation is remarkable, wrote analyst Emmanuel Papadakis in a study released Thursday. However, he remains confident about the upcoming quarterly figures and data on the weight-loss drug Cagrisema./gl/jha/

  Publication of the original study: October 31, 2024 / 8:08 a.m. / CET. First distribution of the original study: Date not specified in study / Time not specified in study / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 30, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "overweight" with a price target of 1,050 Danish kroner. Analyst Richard Vosser compared his estimates with the consensus for the company's quarterly report in early November on Wednesday. According to Vosser, he is 3 percent more cautious about revenue and 2 percent more cautious about earnings figures./ag/edh

  Publication of the original study: October 30, 2024 / 10:25 / GMT

  First distribution of the original study: October 30, 2024 / 10:25 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 28, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner. The weight-loss drug Wegovy continues to show slight week-over-week prescription increases in the US, wrote analyst Jo Walton in his commentary published on Monday./ag/mis/mis

  Publication of the original study: October 28, 2024 / 12:41 / GMT

  First distribution of the original study: October 28, 2024 / 12:41 / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 21, 2024

  Bernstein maintains Novo Nordisk's 'underperform' rating

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Novo Nordisk at "underperform" with a price target of 560 Danish kroner following study data on Rybelsus. The study showed a 14 percent reduction in the risk of major cardiovascular events – defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke – in adult diabetics with heart disease and/or chronic kidney disease compared to placebo. To be clinically significant, the relative risk reduction would have to be slightly higher, according to physicians, analyst Florent Cespedes wrote in a study released Monday. In addition, the absolute risk reduction is likely to be rather small in the end./mis/ajx

  Publication of the original study: October 21, 2024 / 10:39 / UTC

  First distribution of the original study: October 21, 2024 / 10:39 / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 14, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner. Regarding the drug Cagrisema, which consists of two active ingredients, about half of the investors surveyed expect an average weight loss of around 25 percent, wrote analyst Jo Walton in a study released Tuesday. A good half of the investors assume that the tolerability of Cagrisema is similar to that of the appetite suppressant Wegovy, also from Novo Nordisk./bek/tav

  Publication of the original study: October 14, 2024 / 4:58 PM / GMT

  First distribution of the original study: October 14, 2024 / 4:58 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 3, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of 1,100 Danish kroner. Analyst Jo Walton's third-quarter sales forecast is slightly below consensus. The focus will be on the CagriSema combination therapy study, he wrote in his outlook for the interim report published Thursday. Such data could move the pharmaceutical company's shares by more than ten percent./ag/edh

  Publication of the original study: October 3, 2024 / 5:05 a.m. / GMT

  First distribution of the original study: October 3, 2024 / 5:05 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 26, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,050 Danish kroner. Analyst Richard Vosser, in his outlook for the quarterly report released on Friday, expects revenue growth of 21 percent, which is five percent below the consensus. However, Vosser sees potential share price weakness as a good entry opportunity ahead of new pipeline news in the fourth quarter./ag/ajx

  Publication of the original study: September 26, 2024 / 9:04 PM / BST

  First distribution of the original study: September 27, 2024 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 20, 2024

  Goldman maintains Novo Nordisk at 'Buy' - target 1070 kroner

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Novo Nordisk with a price target of 1,070 Danish kroner. The appetite suppressant monlunabant met the lower end of its weight loss expectations in the study, analyst James Quigley wrote in his commentary on Friday. However, the neuropsychiatric side effects were disappointing. In the next phase of the study, the dose will be reduced and a balance between efficacy and side effects will be sought./ag/ajx

  Publication of the original study: September 20, 2024 / 3:17 PM / BST

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 20, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - JPMorgan has maintained Novo Nordisk's "Overweight" rating with a price target of 1,050 Danish kroner. The stock is also on the US bank's "Analyst Focus List." The pharmaceutical company's negative price reaction to study data on monlunabant for weight loss is exaggerated, wrote analyst Richard Vosser in a commentary published Friday. While they confirmed his caution regarding the drug's safety, the data overall confirmed expectations. In view of the data on Cagrisema due in December, the price decline presents a buying opportunity./gl/zb

  Publication of the original study: September 20, 2024 / 5:00 PM / BST First distribution of the original study: September 20, 2024 / 5:00 PM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 20, 2024

  Jefferies leaves Novo Nordisk at 'underperform' - target 575 kroner

  NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained Novo Nordisk's "underperform" rating with a price target of 575 Danish kroner. The pharmaceutical company's study data for monlunabant likely only reached the lower end of expectations for weight reduction, analyst Peter Welford wrote in a commentary published Friday. There are also questions about safety. Therefore, he remains cautious./gl/zb

  Publication of the original study: September 20, 2024 / 10:46 AM / ET First distribution of the original study: September 20, 2024 / 10:46 AM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 20, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained a "neutral" rating on Novo Nordisk with a price target of 1,100 Danish kroner. Following the pharmaceutical company's disappointing study data for monlunabant, investors are likely to write off its already modest contribution to the company's value, analyst Jo Walton wrote in an initial reaction on Friday. However, expectations were already cautious in advance./gl/zb

  Publication of the original study: September 20, 2024 / 2:06 PM / GMT First distribution of the original study: September 20, 2024 / 2:06 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 12, 2024

  Deutsche Bank Research maintains Novo Nordisk's 'Buy' rating

  FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research has maintained its rating for Novo Nordisk at "Buy" with a price target of 1,100 Danish kroner. The safety profile of the weight-loss drug Amycretin appears "not quite as clean" as hoped, wrote analyst Emmanuel Papadakis in his commentary on the presentation of study data at the EASD conference on Thursday./ag/gl

  Publication of the original study: September 12, 2024 / Time not specified in study / CET. First distribution of the original study: September 12, 2024 / 8:15 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 11, 2024

  JPMorgan maintains Novo Nordisk at 'Overweight' - target 1050 kroner

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Novo Nordisk at "Overweight" with a price target of 1,050 Danish kroner. Detailed study data on the weight-loss drug Amycretin underpins its competitiveness, analyst Richard Vosser wrote in his commentary on Wednesday./ag/gl

  Publication of the original study: September 11, 2024 / 12:11 / BST First distribution of the original study: September 11, 2024 / 12:11 / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 11, 2024

  UBS leaves Novo Nordisk at 'Neutral' - target 1100 kroner

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Novo Nordisk at "Neutral" with a price target of DKK 1,100. The weight-loss drug Amycretin appears to be generally well-tolerated, analyst Jo Walton wrote on Wednesday following study data at the EASD conference. Overall, the hope for a next-generation successor for CagriSema is underpinned./ag/gl

  Publication of the original study: September 11, 2024 / 10:45 a.m. / GMT First distribution of the original study: September 11, 2024 / 10:45 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 5, 2024

  Berenberg maintains Novo Nordisk on 'Hold' - target 975 kroner

  HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Hold" rating for Novo Nordisk with a price target of 975 Danish kroner. After a strong start to the year, the share price has recently stalled, analyst Kerry Holford wrote in a report released Friday. This reflects increased investor focus on pricing and competition in the obesity space. She believes that Novo must continue to push forward with a next-generation product generation to maintain its lead and premium valuation./tih/mis

  In our view, Novo must continue to push forward with its next-generation pipeline to maintain its first-mover advantage and premium valuation.

  Publication of the original study: September 5, 2024 / 4:44 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• September 4, 2024

  JPMorgan raises target for Novo Nordisk - 'Overweight'

  NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has raised its price target for Novo Nordisk, which now runs until the end of 2025, to 1,050 Danish kroner, from the previous 950. The rating was maintained at "Overweight." Furthermore, the diabetes specialist's stock is on the "Analyst Focus List" for particularly promising stocks. According to a study released Thursday, analyst Richard Vosser sees important price drivers for the stock in the second half of the year. He refers to upcoming study data on obesity./ck/ajx

  Publication of the original study: September 4, 2024 / 8:53 PM / BST First distribution of the original study: September 5, 2024 / 12:15 AM / BST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• August 28, 2024

  Deutsche Bank maintains Novo Nordisk's 'Buy' rating - target 1,100 kroner

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Novo Nordisk with a price target of DKK 1,100. Unlike before 2022, it has become difficult to keep track of the monthly obesity-related medical literature, analyst Emmanuel Papadakis wrote in a study released Wednesday. In summary, however, it can be said that the latest findings regarding prediabetes are another positive aspect for the market prospects of weight-loss medications./ck/gl

  Publication of the original study: August 28, 2024 / Time not specified in the study / CET. First distribution of the original study: August 28, 2024 / 08:11 / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.